iRadimed Corporation reported a profit of $5.2 million [1] during its second-quarter 2026 financial results conference call on July 31 [2].
The results highlight the company's current growth trajectory as it scales the distribution of new medical hardware. Strong demand for the latest pump model suggests a significant backlog of orders that could drive future revenue.
Based in Orlando, Florida, the company reported net income of $41 million [1] for the quarter. These figures were disclosed during the call recorded on July 31 [2] to provide investors and analysts with operational updates regarding the company's performance.
A primary driver of the current momentum is the 3870 pump. The MSN Tech Editorial Team said bookings for the new device exceeded shipments by more than two times [3]. This gap between orders and deliveries indicates a high level of market adoption for the new technology.
Executives used the call to detail the financial health of the corporation and the specific performance of its product line. The company's ticker, IRMD, reflects these operational shifts as it manages the transition to the 3870 model—a process that has so far outpaced the company's shipping capacity [3].
The conference call served as the official venue for the disclosure of these Q2 metrics [2]. The reporting confirms that the company is maintaining profitability while expanding its footprint in the medical device sector [1].
“iRadimed's new 3870 pump is seeing strong demand”
The disparity between bookings and shipments for the 3870 pump indicates that iRadimed is facing a demand-side surge that exceeds its current supply chain or manufacturing capacity. While the $41 million net income shows strong current health, the company's future growth depends on its ability to convert this massive order backlog into delivered product.
